Alan Venook, MD
Medical Oncology · San Francisco, CANPI 1487618831
Payments from drug & device makers
Across 41 payments — averaging $14,389 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$373K
- Amgen$176K
- Exelixis Inc.$7K
- Merck$6K
- GSK$4K
- E.r. Squibb & Sons, L.L.C.$4K
- plus $20K from 13 others
Across 1 payment — averaging $1125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- QED Therapeutics, Inc.$1K
What the payments were for
- Consulting fees$35,97680%
- Speaking & faculty fees$8,74619%
- Travel & lodging$200%
- Food & beverage$2981%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 1 | $373,393 |
| Amgen | 6 | $175,961 |
| Exelixis Inc. | 9 | $7,161 |
| Merck | 2 | $5,500 |
| GSK | 2 | $4,225 |
| E.r. Squibb & Sons, L.L.C. | 1 | $3,548 |
| Gilead | 1 | $3,040 |
| Genentech USA, Inc. | 2 | $2,751 |
| Intera Oncology, Inc | 4 | $2,500 |
| Bayer | 1 | $2,457 |
| Eisai Inc. | 1 | $2,280 |
| Janssen Scientific Affairs, LLC | 1 | $2,025 |
| Novocure Inc. | 1 | $1,650 |
| Array Biopharma Inc | 1 | $1,460 |
| AbbVie | 1 | $1,100 |
| Seagen Inc. | 1 | $550 |
| Daiichi Sankyo Inc. | 4 | $207 |
| Taiho Oncology, Inc. | 1 | $74 |
| AstraZeneca | 1 | $51 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$589,933 in reported general payments places this provider in the 70th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in San Francisco
- Kevin KimSan Francisco$10.8M
- Amy ChienSan Francisco$10.5M
- Stephen SherwinSan Francisco$6.9M
- Chloe AtreyaSan Francisco$5.7M
- Aman ChauhanSan Francisco$5.2M
- Emily BergslandSan Francisco$3.4M
- Bridget KeenanSan Francisco$2.2M
- Sarmad SadeghiLos Angeles$26.1M
- Marwan FakihDuarte$24.2M
- Sumanta PalDuarte$15.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.